TY - JOUR
T1 - Chromium is the proximate clastogenic species for lead chromate-induced clastogenicity in human bronchial cells
AU - Wise, Sandra S.
AU - Holmes, Amie L.
AU - Ketterer, Michael E.
AU - Hartsock, Wendy J.
AU - Fomchenko, Elena
AU - Katsifis, Spiros
AU - Thompson, W. Douglas
AU - Wise, John Pierce
N1 - Funding Information:
We would like to thank Geron Corporation for the use of the hTERT materials. This work was supported by NIEHS grant 1R01 ES10838 (J.P.W.). MEK and WJH acknowledge support from the National Science Foundation (CHE-0116804) for ICPMS instrumentation.
PY - 2004/5/9
Y1 - 2004/5/9
N2 - Hexavalent chromium (Cr(VI)) is a well-established human lung carcinogen with potentially widespread exposure. Solubility is a key factor in the carcinogenicity of Cr(VI), with the water-insoluble or 'particulate' compounds being the more potent carcinogens. Studies have indicated that the component ions are responsible for their clastogenicity, but it is uncertain whether chromium (Cr), lead (Pb) or some combination of the two is responsible for the clastogenic effects. Accordingly, we compared the clastogenicity of lead chromate (LC) with soluble sodium chromate (SC) and lead glutamate (LG) in WTHBF-6 human lung cells. We found that 1436μM was the maximal intracellular level of Pb after exposure to clastogenic concentrations of LC. However, clastogenesis was not observed after exposure to LG, even when intracellular Pb concentrations reached 13,347μM, indicating that intracellular Pb levels did not reach clastogenic levels in WTHBF-6 cells after LC treatment. By contrast, SC was clastogenic damaging 16 and 44% of metaphase cells at intracellular Cr doses of 312 and 1262μM respectively, which was comparable to the clastogenesis observed after LC treatment. LC damaged 10, 27 and 37% of metaphases at intracellular Cr doses of 288, 926 and 1644μM, respectively. These data indicate that with respect to LC-induced clastogenicity, Cr and not Pb is the proximate clastogenic species in human lung cells.
AB - Hexavalent chromium (Cr(VI)) is a well-established human lung carcinogen with potentially widespread exposure. Solubility is a key factor in the carcinogenicity of Cr(VI), with the water-insoluble or 'particulate' compounds being the more potent carcinogens. Studies have indicated that the component ions are responsible for their clastogenicity, but it is uncertain whether chromium (Cr), lead (Pb) or some combination of the two is responsible for the clastogenic effects. Accordingly, we compared the clastogenicity of lead chromate (LC) with soluble sodium chromate (SC) and lead glutamate (LG) in WTHBF-6 human lung cells. We found that 1436μM was the maximal intracellular level of Pb after exposure to clastogenic concentrations of LC. However, clastogenesis was not observed after exposure to LG, even when intracellular Pb concentrations reached 13,347μM, indicating that intracellular Pb levels did not reach clastogenic levels in WTHBF-6 cells after LC treatment. By contrast, SC was clastogenic damaging 16 and 44% of metaphase cells at intracellular Cr doses of 312 and 1262μM respectively, which was comparable to the clastogenesis observed after LC treatment. LC damaged 10, 27 and 37% of metaphases at intracellular Cr doses of 288, 926 and 1644μM, respectively. These data indicate that with respect to LC-induced clastogenicity, Cr and not Pb is the proximate clastogenic species in human lung cells.
KW - Chromium
KW - Chromosomal aberrations
KW - Clastogenicity
KW - Cytotoxicity
KW - Genotoxicity
KW - Lead chromate
KW - Lung cancer
KW - Sodium chromate
KW - WTHBF-6 cells
UR - http://www.scopus.com/inward/record.url?scp=4043084819&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4043084819&partnerID=8YFLogxK
U2 - 10.1016/j.mrgentox.2004.02.009
DO - 10.1016/j.mrgentox.2004.02.009
M3 - Article
C2 - 15099827
AN - SCOPUS:4043084819
SN - 1383-5718
VL - 560
SP - 79
EP - 89
JO - Mutation Research - Genetic Toxicology and Environmental Mutagenesis
JF - Mutation Research - Genetic Toxicology and Environmental Mutagenesis
IS - 1
ER -